A Phase III study comparing tusamitamab ravtansine with docetaxel in patients with advanced non-squamous non-small cell lung cancer (NSCLC) previously treated with platinum-based chemotherapy and immunotherapy (in combination or sequential), whose tumors highly expressed CEACAM5, was presented at the International Association for the Study of Lung Cancer 2024 World Conference on Lung Cancer in San Diego, Calf., by Dr. Benjamin Besse of Gustave Roussy, in Paris, France.
Results from study of tusamitamab ravtansine vs. docetaxel in previously treated advanced non-squamous NSCLC
Tech News
-
Free Dark Web Monitoring Stamps the $17 Million Credentials Markets
-
Smart buildings: What happens to our free will when tech makes choices for us?
-
Screenshots have generated new forms of storytelling, from Twitter fan fiction to desktop film
-
Darknet markets generate millions in revenue selling stolen personal data, supply chain study finds
-
Privacy violations undermine the trustworthiness of the Tim Hortons brand
-
Why Tesla’s Autopilot crashes spurred the feds to investigate driver-assist technologies – and what that means for the future of self-driving cars